We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
ITRACONAZOLE PHARMACOR (Pharmacor Pty Ltd)
Product name
ITRACONAZOLE PHARMACOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
144 (255 working days)
Active ingredients
Itraconazole
Registration type
New generic medicine
Indication
[TRADENAME] is indicated for use in adults for the treatment of:
- Superficial dermatomycoses not responding to topical treatment.
- Fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening.
- Pityriasis versicolor not responding to any other treatment.
- Vulvovaginal candidiasis not responding to topical treatment.
- Oral candidiasis in immunocompromised patients.
- Onychomycosis caused by dermatophytes.
- Systemic mycoses, only in the following fungal infections:
- Systemic aspergillosis, histoplasmosis, lymphocutaneous/cutaneous sporotrichosis.
- Treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection.
- Treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective.
- Treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.